|
|
 | | | |
- close
- close
- close
- close
Opexa Therapeutics (OPXA) |
StreetInsider.com
May 14
Comment
PDI, Inc. (Nasdaq: PDII) 30.8% HIGHER; reported Q1 EPS of $0.14, $0.25 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $42.9 million versus the consensus estimate of $38.02 million.
Opexa Therapeutics, Inc....
Benzinga
May 14
Comment
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) fell 18.86% to $4.22 at 9:59 am. Oxygen Biotherapeutics announced its 20:1 reverse stock split effective after market close on May 10th, on Friday.
Stereotaxis Inc. (NASDAQ: STXS) shares dipped...
StreetInsider.com
Apr 1
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Opexa+Therapeutics+%28OPXA%29+Widens+Loss+in+FY12/8220205.html for the full story.
TheStreet.com
Mar 15
Comment
WINDERMERE, Fla. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.
Stocks that are making large moves like these are favorites among short-term traders...
Benzinga
Mar 12
Comment
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Opexa Therapeutics
Shares of Opexa Therapeutics (NASDAQ: OPXA), the Woodlands, TX biopharmaceutical company rose 14.5% Tuesday on 3.5 times average...
Benzinga
Feb 7
Comment
Opexa Therapeutics (NASDAQ: OPXA) a company developing Tcelna™ (imilecleucel-T), a novel T-cell therapy for multiple sclerosis (MS), today announced it has priced an offering of shares of its common stock and warrants to purchase common stock in...
TheStreet.com
Feb 5
Comment
THE WOODLANDS, Texas (TheStreet) -- Nothing screams Biotech Bubble like Opexa Therapeutics .
Opexa shares nearly quadrupled in early Tuesday trading because the company signed a small option deal for its multiple sclerosis drug Tcelna with...
FierceBiotech
Feb 5
Comment
Close to two years after Merck KGaA was forced to concede the embarrassing collapse of its oral multiple sclerosis program for cladribine, its Serono unit has picked up a cheap option on the global rights to a little-known therapeutic vaccine for...
StreetInsider.com
Feb 5
Comment
Opexa Therapeutics, Inc. (NASDAQ: OPXA) 300% HIGHER; announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna (imilecleucel-T), a potential...
Wall Street Journal
Feb 5
Comment
Among the companies with shares expected to trade actively in Tuesday's session are Yum Brands, Idenix Pharmaceuticals and Opexa Therapeutics.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
